


Investment Objective and Benchmark Index

The Biotech Growth Trust PLC seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

Five Year Performance (%)

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed; an investor may receive back less than the original amount invested.



— Share Price (total return) +113.3%
 — Net Asset Value per share (total return) +98.7%
 — Benchmark: NASDAQ Biotechnology Index (sterling adjusted) +66.7%

Source: Morningstar, Index - Bloomberg.

Ten Largest Holdings as at 31 May 2021 (% of total investments)

| Name | Total |
|---------------------------|-------------|
| Vertex Pharmaceuticals | 5.8 |
| Singular Genomics Systems | 4.2 |
| Neurocrine Biosciences | 3.8 |
| Horizon Therapeutics | 3.6 |
| Alexion Pharmaceuticals | 3.1 |
| Magenta Therapeutics | 2.9 |
| Curis | 2.7 |
| Aptose Biosciences | 2.7 |
| Keros Therapeutics | 2.6 |
| Biogen | 2.6 |
| Total | 34.0 |



Portfolio Manager Geoffrey Hsu



OrbiMed
 Healthcare Fund Management

Fast Facts

As at 31 May 2021

Launch Date June 1997

AIC Sector Biotechnology & Healthcare

Date of Appointment of OrbiMed
 19 May 2005

Annual Management Fee to 31 March 2021 (payable by the Company)

0.65% of net assets plus 0.30% per annum on the Company's market cap up to £500m, 0.20% on market capitalisation above £500m to £1bn and 0.10% on market capitalisation over £1bn

Performance fee See Annual Report for details

Ongoing Charges Ratio (OCR) * 1.1%

Continuation Vote 2025 AGM and every 5th AGM thereafter

Year / interim end 31 March / 30 September

Capital Structure 41,684,769 Ordinary Shares of 25p

Trust Characteristics

Number of Holdings 86

Net Assets (£m) £559.9m

Market Capitalisation (£m) £561.9m

Dividend Policy It is not anticipated that the Company will pay a dividend

Gearing (AIC basis) 7.9%

Leverage** Gross
 109.5%
 Commitment
 109.1%

Share Price (p) 1348.00

NAV (p) 1343.24

Premium / (Discount) 0.4%

Portfolio Turnover p.a. 107.5%

Active Share*** 79.4%

Geographical Breakdown as at 31 May 2021 (%)

| | |
|--------------------|---------------|
| North America | 76.0% |
| China (quoted) | 9.3% |
| Continental Europe | 7.4% |
| *Unquoted | 6.0% |
| Singapore | 0.8% |
| United Kingdom | 0.5% |
| Total | 100.0% |

* No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to invest in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. Of the 6.0% unquoted investments, 2.4% is classified as North America, 3.3% as China, and 0.3% as Asia.

Source: All portfolio information sourced from Frostrow Capital LLP

Discrete Performance – Calendar Years (%)

| Percentage Growth 12 Month Return | 2016 | 2017 | 2018 | 2019 | 2020 | YTD |
|-----------------------------------|------|------|-------|------|------|-------|
| NAV | -7.6 | 9.9 | -14.3 | 47.4 | 52.4 | -12.6 |
| Share Price | -4.7 | 12.1 | -19.9 | 48.5 | 67.7 | -14.5 |
| Index | -6.5 | 10.5 | -3.8 | 19.6 | 22.1 | -3.7 |

Standardised Discrete Performance (%)

| Percentage Growth 12 Month Return | May 16- May 17 | May 17- May 18 | May 18- May 19 | May 19- May 20 | May 20- May 21 |
|-----------------------------------|----------------|----------------|----------------|----------------|----------------|
| NAV | 12.4 | 4.0 | -5.0 | 67.1 | 7.1 |
| Share Price | 11.6 | 4.6 | -4.9 | 68.4 | 14.0 |
| Index | 15.2 | 10.4 | -3.0 | 38.1 | -2.2 |

Past performance is not a guide to future performance. The value of investments and the income from them may fall as well as rise and is not guaranteed.

Source: NAV (total return; fully diluted) & Share Price (total return) – Morningstar. Index - Bloomberg.

*Calculated at the financial year end, includes management fees and all other operating expenses, excludes performance fees.

**The Board has set the leverage limit for both the Gross and the Commitment basis at 130% of the Company's Net Asset Value.

***Active Share is expressed as a percentage and shows the extent to which a fund's holdings and their weightings differ from those of the fund's benchmark index. A fund that closely tracks its index might have a low Active Share of less than 20% and be considered passive, while a fund with an Active Share of 60% or higher is generally considered to be actively managed.


Codes

| | |
|---|----------------------|
| Sedol | 0038551 |
| ISIN | GB0000385517 |
| Legal Entity Identifier (LEI) | 549300Z41EP32MI2DN29 |
| Global Intermediary Identification Number (GIIN) | U1MQ70.99999.SL.826 |
| Bloomberg | BIOG LN |
| EPIC | BIOG |

Investment Policy

In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. No more than 10% of gross assets will be invested in unquoted investments at the time of acquisition. This limit includes any investment or commitment to invest in private equity funds managed by OrbiMed or an affiliate thereof. Investments or commitments to investment in such private equity funds will be limited to US\$15m, after the deduction of proceeds of disposal and other returns of capital. The Company's borrowing policy is that borrowings will not exceed 20% of the Company's net assets. The Company may be unable to invest directly in certain countries. In these circumstances, the Company may gain exposure to companies in such countries by investing indirectly through swaps. Where the Company invests in swaps, exposure to underlying assets will not exceed 5% of the gross assets of the Company at the time of entering into the contract.

Return vs Volatility (5 Years Annualised) – Chart (%)



Commentary

In May, the NAV per share was down 5.8%, the share price was down 6.9% and the benchmark NASDAQ Biotechnology Index (sterling adjusted) was down 4.6%.

In May, biotechnology continued its underperformance versus the broader market. The continued rotation into value from growth stocks has remained an overhang on the high-growth biotechnology sector. We expect merger and acquisition activity, the appointment of a permanent U.S. FDA commissioner, and positive clinical data for the sector could help turn around sentiment.

The pace of COVID-19 vaccinations in the U.S. has slowed down, with approximately 46% of adults fully vaccinated in the country. During the month, the U.S. FDA granted its first Emergency Use Authorization (EUA) for a vaccine in adolescents ages 12-15. We believe wide-scale vaccinations of the younger population will be key to reach herd immunity and allow for full re-opening. Worldwide, the vaccine rollout has continued at a slower pace, though we expect supply constraints to ease throughout 2021 and allow for more rapid distribution. While variant strains of COVID-19 have raised concerns in countries like India, we continue to see good evidence that currently available vaccines should confer protection against these variants. We anticipate data from clinical trials assessing both variant-specific vaccines and booster shots to be available in the third quarter, which will be key in understanding the longer-term dynamics of COVID-19 vaccination regimens.

Curis, HBM Holdings, and Alphamab Oncology were the largest positive contributors to performance during the month. Shares of Curis were strong following the disclosure of updated data in an abstract from the European Hematology Association meeting. Data in the abstract showed encouraging activity of CA-4948 in acute myeloid leukemia, which we see as intriguing early proof-of-concept data for the drug's novel mechanism. Alphamab Oncology shares appreciated in anticipation of clinical data for the company's anti-cancer antibodies at the American Society of Clinical Oncology Annual Meeting in June. Shares of HBM Holdings outperformed on no fundamental news.

ImmunoGen, Guardant Health, and Novavax were the largest negative contributors to performance during the month. Shares of ImmunoGen were weak following the announcement of a delay in the key Phase 3 trial readout for mirvetuximab in ovarian cancer to 4Q21 from 3Q21, attributed to COVID-19-related enrolment slowdowns. We continue to anticipate positive data from the trial despite the delay. Guardant Health shares underperformed as investors were underwhelmed by the company's financial guidance for 2021; we view the guidance as both achievable and conservative. Shares of Novavax were weak as news outlets reported slight delays for the key Phase 3 data from the company's COVID-19 vaccine. We believe the Novavax vaccine has shown strong data to date and anticipate a near-term EUA, following additional data.

Discount Control Mechanism

The Directors have adopted an active discount management policy to establish and support an improved rating in the Company's shares through the use of share buybacks, with a view to limiting the discount to NAV per share at which the shares trade to no more than 6%. Shares bought back will be cancelled.

How to Contact Us

Frostrow Capital LLP
25 Southampton Buildings
London, WC2A 1AL

Tel.: 0203 008 4910
Fax: 0203 043 8889

Website: www.frostrow.com
Email: info@frostrow.com



Risk Warnings

This document is for information purposes only and does not constitute an offer or invitation to purchase shares in the Company and has not been prepared in connection with any such offer or invitation. Before investing in the Company, or any other investment product, you should satisfy yourself as to its suitability and the risks involved, and you may wish to consult a financial adviser.

Any return you receive depends on future market performance and is uncertain. The Company does not seek any protection from future market performance so you could lose some or all of your investment. Shares of the Company are bought and sold on the London Stock Exchange (LSE). The price you pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company. Usually, at any given time, the price you pay for a share will be higher than the price you could sell it. For further information on the principal risks the Company is exposed to please refer to the Company's Annual Report or Investor Disclosure Document available at www.biotechgt.com. The Company can borrow to purchase investments, this could potentially magnify any losses or gains made by the Company.

Important Information

The Biotech Growth Trust PLC is a public limited company whose shares are premium listed on the LSE and is registered with HMRC as an investment trust. The Company has an indeterminate life, although shareholders consider and vote on the continuation of the Company every five years (the next such vote will be held in 2020).